Can celebrex tame chemo side effects in colon cancer?
NCT ID NCT00159484
First seen May 30, 2026 · Last updated Jun 20, 2026 · Updated 3 times
Summary
This study tested whether adding Celebrex to the experimental drug EPO906 could reduce severe diarrhea in people with advanced colorectal cancer. It involved 75 patients who had already tried standard treatments. The first phase found the safest dose, and the second phase looked at how tumors responded.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
U.S.C./Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Celecoxib (Celebrex) and epothilone B (EPO906)
What this could lead to
If successful, this could show that adding Celebrex to EPO906 reduces severe diarrhea and helps control tumor growth in advanced colorectal cancer.
What could go wrong
This is an early-phase trial with a small number of participants. The experimental drug EPO906 may cause side effects, and the combination may not work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.